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Abstract 
Background: Targeting BRAF V600E mutation has been proven effective in the treatment of several types of can‑
cer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF 
oncogene may represent a plausible therapeutic strategy for the rare patients with BRAF‑mutated endometrial cancer 
remains to be ascertained in prospective studies.
Case presentation: We report herein the case of a heavily pre‑treated patient with recurrent microsatellite instabil‑
ity high (MSI‑H) BRAF V600E mutated endometrial adenocarcinoma, which was successfully treated with the V600E 
targeting agent dabrafenib. After developing resistance to this agent, the MEK targeting agent trametinib was added 
to dabrafenib achieving again a therapeutic response.
Conclusions: This case shows that dabrafenib both as monotherapy and when combined with trametinib may exert 
significant therapeutic activity in heavily pretreated BRAF V600E mutated endometrial adenocarcinoma, and highlight 
potential benefits of personalized treatment in this disease.
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Background
Endometrial cancer is the most frequent gynecologi-
cal tumor in developed countries, and its incidence is 
increasing [1]. Most patients are diagnosed with early 
stage disease confined to the uterus, and treated with 
combination of surgery and adjuvant chemotherapy 
depending on histology and stage [1]. Metastatic disease 
is however characterized by a dismal prognosis due to 
limited therapeutic options mainly based on platinum 
and taxane chemotherapy [2, 3].
The advent of sequencing technologies allowing for 
rapid, low cost, and accurate sequencing of clinical 
samples, has led to a different approach, namely person-
alized therapy, to the treatment of cancer based on tar-
get therapies; whether this approach increases survival 
compared to the conventional chemotherapy-based one 
remains to be ascertained [4].
Of note, the therapeutic activity of tumor-targeted 
agents depends not only on the presence of a specific tar-
getable mutation, but also on the specific tumor type that 
harbors the mutation.
For example, agents targeting the BRAF V600E muta-
tion can lead to impressive response rate in BRAF V600E 
mutated melanoma [5] and hairy cell leukemia [6], alone 
or when combined with a MEK targeting agent [7]; inter-
mediate activity has been observed in BRAF mutated 
non-small cell lung cancer [8] and thyroid cancer [9], 
while minimal activity has been achieved in BRAF V600E 
mutated colorectal cancers [10].
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BRAF mutations have been found in 15% of all cancer 
with BRAF V600E mutation being the most well charac-
terized mutation leading to dysregulated BRAF activa-
tion [11].
In endometrial cancer, the frequency of BRAF muta-
tions have been reported as being very low and occurring 
with a frequency of 2–5% depending on the specific case 
series [12]. Incidence of BRAF V600E mutation is esti-
mated as 0.1% in the largest case series reported so far 
[12]. Contrary to what has been described in colorectal 
cancer, no association with microsatellite (MSI) status 
has been found [13].
Whether BRAF targeting agents may exert therapeu-
tic activity in BRAF V600E mutated endometrial cancer 
remains to be determined.
To the best of our knowledge, here we provide first 
evidence that a BRAF targeting agent has therapeutic 
activity in endometrial cancer harboring a BRAF V600E 
mutation both alone and when combined with a MEK 
inhibitor.
Case report
In 2001, a 49-year-old patient underwent total abdomi-
nal hysterectomy and bilateral salpingo-oophorectomy 
for a stage FIGO 1b well differentiated adenocarcinoma 
of the endometrium with early myometrial invasion, no 
adjuvant therapy was indicated. Eleven years after the 
initial diagnosis a recurrence in the left pelvic sidewall 
was identified by PET–CT imaging. She received 6 cycle 
of carboplatin/paclitaxel chemotherapy followed by radi-
cal radiotherapy with good partial response, and a small 
residual soft tissue remaining in the left pelvic side wall.
Two years later a CT scan showed significant increase 
in size of the pelvic soft tissue mass and she was treated 
with letrozole based on a 30% estrogen receptor positiv-
ity identified on histopathological review of the original 
tumor tissue, but rapidly progressed after 2  months of 
treatment. The tumor tissue was further tested for MSI 
status and BRAF mutational status and found to be MSI-
high and to harbor a BRAF V600E mutation.
Immunohistochemistry for MLH1, PMS2, MSH2, and 
MSH6 proteins was first used to evaluate microsatellite 
status but results were inconclusive due to poor fixation 
of the tissue. Microsatellite status was then investigated 
by PCR with 4 out of 5 microsatellite markers analyzed 
(BAT-25, BAT-26, MONO-27, NR-21, NR-24) showing 
evidence of instability confirming that the tumor was 
indeed MSI-high. BRAF mutational status was evaluated 
by standard PCR-based approach.
Given the patient’s cancer family history notable for 
her father and aunt developing colon cancer, her mother 
developing pancreatic cancer and her sister developing 
breast cancer—BRCA 1/2 mutational testing, as well as 
Lynch syndrome germline mutation testing were under-
taken but no mutations were identified.
She then received second line chemotherapy with gem-
citabine and carboplatin completing 6 cycles; an end of 
treatment CT scan showed disease progression with 
development of new bilateral lung metastases.
The patient was subsequently enrolled in a phase 1 clin-
ical trial (NCT02223247) and treated with a combination 
of weekly paclitaxel and a fatty acid synthase inhibitor. A 
gradual interval increase in the size of the lung metasta-
ses and the left pelvic sidewall mass was observed on 8 
weekly CT scans, meeting the criteria of disease progres-
sion by RECIST 1.1 after 5 cycles of treatment (Fig. 1a, e).
As she had evidence of BRAF V600E mutation, she was 
then enrolled on another clinical trial (a phase 1 Pharma-
cokinetics Study of the Effects Rabeprazole and Rifampin 
on Dabrafenib in Subjects with BRAF V600 Mutation 
Positive Tumors, NCT01954043) and commenced treat-
ment with therapeutic dose of dabrafenib 150 mg BD in 
combination with rabeprazole and rifampin for only the 
first cycle, tolerating treatment with few side effects. A 
CT scan performed after the initial 3 months of treatment 
showed reduction in size of all the lung metastases and 
the left pelvic soft tissue mass (Fig. 1b, f ). Subsequent CT 
scan performed after an additional 3 months of dabafenib 
monotherapy showed continued response of the lung 
metastases (Fig. 1g), but slight increase of the size of the 
pelvic mass (Fig. 1c). Thus, 6 months after commencing 
dabrafenib, trametinib 2  mg therapeutic dose was com-
menced in combination with dabrafenib within a named 
patient access program. A re-staging CT scan performed 
after 3 months of combination treatment showing main-
tained response of the lung metastases and stable size 
of pelvic mass (Fig. 1d, h). At the time of reporting, the 
patient remains on treatment without experiencing any 
side effects and with maintained response.
Discussion
To the best of our knowledge, this is the first report show-
ing clinical utility of dabrafenib, alone or combined with 
trametinib, in a patient with BRAF V600E mutated endo-
metrial adenocarcinoma. Among gynecological cancers, 
activating BRAF mutations have been more frequently 
found in low grade ovarian cancers, but are extremely 
rare in other histological types of ovarian cancers, in cer-
vical carcinomas, and in endometrial carcinomas [12]. In 
endometrial carcinomas, most of the series have shown 
a very low prevalence of BRAF mutations with BRAF 
V600E mutation being very rarely found [13].
The present report highlights the importance of molec-
ular characterization of sporadic cancers that can unex-
pectedly open new therapeutic options for patients. 
Precision medicine refers to therapeutic decisions guided 
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by the molecular or genomic features of a tumour rather 
than on the basis of clinicopathological features; this 
novel approach has successfully been applied in this case 
with significant benefit for the patient; in fact, progres-
sion after the third line of chemotherapy would have left 
this patient without further conventional therapeutic 
options. However, with the revelation of an actionable 
mutation, this patient received a BRAF targeting agent 
with subsequent benefit. Although the benefits of preci-
sion medicine and personalized treatment in oncology 
have been recently put into question by the SHIVA trial 
[4], this case illustrates that at least for some patients per-
sonalized treatment may significantly impact on survival 
and prognosis. In this context, results from the ongoing 
MOSCATO trial (NCT01566019) are largely awaited. In 
order to maximize benefits of personalized treatment, 
future prospective studies need to be better designed 
through better patients’ selection based on strong and 
reliable biomarkers, and new potent and selective inhibi-
tors should be developed.
The presence of an activating BRAF V600E muta-
tion associates with microsatellite instability in sporadic 
colon-cancer tumors but not in those secondary to Lynch 
syndrome [14] and is mostly due to hypermethylation of 
MLH1 gene promoter [14]. In endometrial cancer a MSI 
high status has been reported in 15% of unselected endo-
metrial cancer cases [15]; however, an absence of correla-
tion between MSI status and BRAF V600E mutation has 
been reported [13], although giving the extreme rarity of 
the mutation in this disease, this association would be 
hard to be demonstrated.
Interestingly, this patient’s tumor was found to be both 
MSI high and to carry an activating mutation of the BRAF 
gene. Of note, genetic screening for Lynch syndrome was 
negative, suggesting, at least for this case, that the MSI 
and BRAF mutational status may correlate in sporadic but 
not in Lynch syndrome associated endometrial cancers, 
similarly to what described for colorectal cancers.
Of importance, MSI high tumors are known to have 
a high mutation load, which has been correlated with 
increased PD-1 expression and higher T-cytotoxic cell 
infiltration [16]. Data from a recently published phase 2 
trial of pembrolizumab, an anti-PD-1 inhibitor, supports 
the hypothesis MSI high tumors, including endometrial 
cancers, are highly responsive to immune checkpoint 
blockade. Of note in this study, 1 complete response and 
1 partial response were observed among the two endo-
metrial cancer patients enrolled [17]. This preliminary 
clinical evidences suggest that this patient will possibly 
benefit by an anti-PD-1/PD-L1 agent in the future, fur-
ther demonstrating the importance of molecular charac-
terization of sporadic cancers.
After developing partial resistance to dabrafenib this 
patient received a MEK inhibitor in addition to dab-
rafenib, which at least in melanoma patients, has shown 
to both reverse resistance to BRAF target agents and to 
significantly prolong survival compared to BRAF target-
ing agent monotherapy [7].
Fig. 1 Representative CT scan images of target lesions showing response to dabrafenib monotherapy and dabrafenib and trametinib combina‑
tion. Patient started treatment and showed response at the first 3 monthly CT scan (b, f) in all target lesions compared to the baseline (a, e). At the 
second 3 monthly CT scan the pelvic mass showed increased size (panel c, indicated by straight red line) compared to baseline while pulmonary 
metastases showed maintained response (panel g, representative image). Introduction of trametinib halted further progression of the pelvic mass 
(panel d) and induced further regression of the pulmonary metastases (panel h) suggesting that MEK inhibition can synergize and revert resistance 
to BRAF targeting agents in endometrial cancer harboring BRAF V600F mutation
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In line with this evidence, the addition of the MEK inhibi-
tor trametinib lead to resensitization of the tumor to the 
upstream inhibition of BRAF oncogene, thus further pro-
longing response to BRAF inhibitor based treatment and 
suggesting that combination of target treatments can be 
a better therapeutic strategy for this type of disease. This 
hypothesis is supported by the evidence that selumetinib, 
another selective, orally-available, MEK inhibitor [18], has 
shown minimal single agent activity in a phase II, single-arm, 
open-label study conducted in 54 recurrent EC patients [19]. 
However, an ongoing randomized trial in endometrial can-
cer patients (GOG-229O) is currently investigating the activ-
ity of trametinib versus the combined MEK/AKT inhibition 
with GSK2141795 and trametinib (NCT01935973) and will 
provide further evidences supporting this hypothesis.
Conclusions
This case illustrates the importance of molecular charac-
terization of sporadic cancers and the potential impact 
that personalized therapy can have on the prognosis of 
cancer bearing actionable mutations. Importantly, this 
case shows that MAPK pathway plays a central role in the 
pathogenesis of a subset of endometrial cancers and that 
BRAF and MEK inhibitors may exert significant anti-
tumor activity in BRAF V600E mutated endometrial can-
cers, calling for prospective confirmatory clinical studies 
to be carried out in this setting.
Abbreviations
BRAF: B‑rapid accelerated fibrosarcoma; MEK: mitogen‑activated protein/
extracellular signal‑regulated kinase kinase; MSI‑H: microsatellite instability 
high; BRCA 1/2: breast cancer susceptibility protein ½; RECIST 1.1 criteria: 
response evaluation criteria in solid tumors criteria.
Authors’ contributions
MM and HTA wrote/edited the final manuscript. GM, JH, CD, MU managed 
patient’s care in our Drug Development Unit. All authors read and approved 
the final manuscript.
Author details
1 Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, 
London W1G 6AD, UK. 2 University College London, London, UK. 
Acknowledgements
We are extremely grateful to the patient and her family for the participation in 
this clinical study.
Competing interests
All authors declare that they have no competing interests.
Availability of data and materials
The authors did not use any datasets, databases, or software in writing the 
manuscript.
Consent for publication
The authors obtained informed consent from the patient to publish informa‑
tion on her disease and clinical course.
Ethical approval and consent to participate
Not applicable. The authors obtained patient’s consent for publication of her 
disease history.
Received: 1 December 2016   Accepted: 29 December 2016
References
 1. Morice P, Leary A, Creutzberg C, Abu‑Rustum N, Darai E. Endometrial 
cancer. Lancet. 2016;387:1094–108.
 2. Group SGOCPECW, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, 
Olawaiye AB, Brewer M, Boruta D, Villella J, et al. Endometrial cancer: 
a review and current management strategies: part I. Gynecol Oncol. 
2014;134:385–92.
 3. Group SGOCPECW, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, 
Olawaiye AB, Brewer M, Boruta D, Herzog TJ, et al. Endometrial cancer: 
a review and current management strategies: part II. Gynecol Oncol. 
2014;134:393–402.
 4. Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, 
Campone M, Tredan O, Massiani MA, Mauborgne C, et al. Molecularly 
targeted therapy based on tumour molecular profiling versus conven‑
tional therapy for advanced cancer (SHIVA): a multicentre, open‑label, 
proof‑of‑concept, randomised, controlled phase 2 trial. Lancet Oncol. 
2015;16:1324–34.
 5. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, 
Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al. Dabrafenib in 
BRAF‑mutated metastatic melanoma: a multicentre, open‑label, phase 3 
randomised controlled trial. Lancet. 2012;380:358–65.
 6. Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin 
S, Pulsoni A, Chung YR, et al. Targeting mutant BRAF in relapsed or refrac‑
tory hairy‑cell leukemia. N Engl J Med. 2015;373:1733–47.
 7. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroia‑
kovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved 
overall survival in melanoma with combined dabrafenib and trametinib. 
N Engl J Med. 2015;372:30–9.
 8. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, 
Smit EF, Groen HJ, Kelly RJ, et al. Dabrafenib in patients with BRAF(V600E)‑
positive advanced non‑small‑cell lung cancer: a single‑arm, multicentre, 
open‑label, phase 2 trial. Lancet Oncol. 2016;17:642–50.
 9. Falchook GS, Millward M, Hong D, Naing A, Piha‑Paul S, Waguespack SG, 
Cabanillas ME, Sherman SI, Ma B, Curtis M, et al. BRAF inhibitor dabrafenib 
in patients with metastatic BRAF‑mutant thyroid cancer. Thyroid. 
2015;25:71–7.
 10. Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, Morris V, 
Janku F, Dasari A, Chung W, et al. Phase II pilot study of vemurafenib in 
patients with metastatic BRAF‑mutated colorectal cancer. J Clin Oncol. 
2015;33:4032–8.
 11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Wof‑
fendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in 
human cancer. Nature. 2002;417:949–54.
 12. Moreno‑Bueno G, Sanchez‑Estevez C, Palacios J, Hardisson D, Shiozawa T. 
Low frequency of BRAF mutations in endometrial and in cervical carcino‑
mas. Clin Cancer Res. 2006;12(3865):3865–6.
 13. Metcalf AM, Spurdle AB. Endometrial tumour BRAF mutations and 
MLH1 promoter methylation as predictors of germline mismatch 
repair gene mutation status: a literature review. Fam Cancer. 
2014;13:1–12.
 14. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian 
ZR, Morikawa T, Shen J, Meyerhardt JA, et al. Microsatellite instability and 
BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer 
Inst. 2013;105:1151–6.
 15. Kanopiene D, Smailyte G, Vidugiriene J, Bacher J. Impact of microsatellite 
instability on survival of endometrial cancer patients. Medicina (Kaunas). 
2014;50:216–21.
 16. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover 
E, Strickland KC, D’Andrea AD, Wu CJ, et al. Association of polymer‑
ase e‑mutated and microsatellite‑instable endometrial cancers with 
Page 5 of 5Moschetta et al. Exp Hematol Oncol  (2017) 6:1 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
neoantigen load, number of tumor‑infiltrating lymphocytes, and expres‑
sion of PD‑1 and PD‑L1. JAMA Oncol. 2015;1:1319–23.
 17. Asaoka Y, Ijichi H, Koike K. PD‑1 blockade in tumors with mismatch‑repair 
deficiency. N Engl J Med. 1979;2015:373.
 18. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry 
J, Smith D, Brandhuber BJ, Gross S, et al. Biological charac‑
terization of ARRY‑142886 (AZD6244), a potent, highly selective 
mitogen‑activated protein kinase kinase 1/2 inhibitor. Clin Cancer 
Res. 2007;13:1576–83.
 19. Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, John‑
ston CM, Rotmensch J. A phase II evaluation of selumetinib (AZD6244, 
ARRY‑142886), a selective MEK‑1/2 inhibitor in the treatment of recurrent 
or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncol‑
ogy Group study. Gynecol Oncol. 2015;138:30–5.
